Literature DB >> 22340589

Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox.

Gen-Sheng Feng1.   

Abstract

In delineating the molecular pathogenesis of hepatocellular carcinoma (HCC), recent experiments in mouse tumor models have revealed unexpected tumor-suppressing effects in genes previously identified as pro-oncogenic. This contradiction underscores the complexity of hepatocarcinogenesis and predicts uncertainty in targeting these molecules for HCC therapy. Deciphering the underlying mechanisms for these paradoxical functions will elucidate the complex molecular and cellular communications driving HCC development, and will also suggest more thoughtful therapeutic strategies for this deadly disease. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22340589      PMCID: PMC3285429          DOI: 10.1016/j.ccr.2012.01.001

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  32 in total

Review 1.  Met, metastasis, motility and more.

Authors:  Carmen Birchmeier; Walter Birchmeier; Ermanno Gherardi; George F Vande Woude
Journal:  Nat Rev Mol Cell Biol       Date:  2003-12       Impact factor: 94.444

2.  Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation.

Authors:  Toshiharu Sakurai; Shin Maeda; Lufen Chang; Michael Karin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-28       Impact factor: 11.205

3.  c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.

Authors:  Hanning You; Wei Ding; Hien Dang; Yixing Jiang; C Bart Rountree
Journal:  Hepatology       Date:  2011-07-19       Impact factor: 17.425

4.  Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma.

Authors:  Tom Luedde; Naiara Beraza; Vasileios Kotsikoris; Geert van Loo; Arianna Nenci; Rita De Vos; Tania Roskams; Christian Trautwein; Manolis Pasparakis
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

Review 5.  N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation.

Authors:  L Verna; J Whysner; G M Williams
Journal:  Pharmacol Ther       Date:  1996       Impact factor: 12.310

6.  IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis.

Authors:  Shin Maeda; Hideaki Kamata; Jun-Li Luo; Hyam Leffert; Michael Karin
Journal:  Cell       Date:  2005-07-01       Impact factor: 41.582

7.  NF-kappaB functions as a tumour promoter in inflammation-associated cancer.

Authors:  Eli Pikarsky; Rinnat M Porat; Ilan Stein; Rinat Abramovitch; Sharon Amit; Shafika Kasem; Elena Gutkovich-Pyest; Simcha Urieli-Shoval; Eithan Galun; Yinon Ben-Neriah
Journal:  Nature       Date:  2004-08-25       Impact factor: 49.962

8.  Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis.

Authors:  Taro Takami; Pal Kaposi-Novak; Koichi Uchida; Luis E Gomez-Quiroz; Elizabeth A Conner; Valentina M Factor; Snorri S Thorgeirsson
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

9.  Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas.

Authors:  A de La Coste; B Romagnolo; P Billuart; C A Renard; M A Buendia; O Soubrane; M Fabre; J Chelly; C Beldjord; A Kahn; C Perret
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

10.  Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice.

Authors:  R Wang; L D Ferrell; S Faouzi; J J Maher; J M Bishop
Journal:  J Cell Biol       Date:  2001-05-28       Impact factor: 10.539

View more
  57 in total

1.  ALDH2(E487K) mutation increases protein turnover and promotes murine hepatocarcinogenesis.

Authors:  Shengfang Jin; Jiang Chen; Lizao Chen; Gavin Histen; Zhizhong Lin; Stefan Gross; Jeffrey Hixon; Yue Chen; Charles Kung; Yiwei Chen; Yufei Fu; Yuxuan Lu; Hui Lin; Xiujun Cai; Hua Yang; Rob A Cairns; Marion Dorsch; Shinsan M Su; Scott Biller; Tak W Mak; Yong Cang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-06       Impact factor: 11.205

2.  Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation.

Authors:  Simona Hefetz-Sela; Ilan Stein; Yair Klieger; Rinnat Porat; Moshe Sade-Feldman; Farid Zreik; Arnon Nagler; Orit Pappo; Luca Quagliata; Eva Dazert; Robert Eferl; Luigi Terracciano; Erwin F Wagner; Yinon Ben-Neriah; Michal Baniyash; Eli Pikarsky
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-24       Impact factor: 11.205

3.  Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis.

Authors:  Wantae Kim; Sanjoy Kumar Khan; Jelena Gvozdenovic-Jeremic; Youngeun Kim; Jason Dahlman; Hanjun Kim; Ogyi Park; Tohru Ishitani; Eek-Hoon Jho; Bin Gao; Yingzi Yang
Journal:  J Clin Invest       Date:  2016-11-21       Impact factor: 14.808

Review 4.  STAT3 in hepatocellular carcinoma: new perspectives.

Authors:  Jasmin Svinka; Wolfgang Mikulits; Robert Eferl
Journal:  Hepat Oncol       Date:  2013-12-20

5.  Akt-ing up on SRPK1: oncogene or tumor suppressor?

Authors:  Alex Toker; Y Rebecca Chin
Journal:  Mol Cell       Date:  2014-05-08       Impact factor: 17.970

Review 6.  Revisiting the hallmarks of cancer.

Authors:  Yousef Ahmed Fouad; Carmen Aanei
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

Review 7.  Mouse models for liver cancer.

Authors:  Latifa Bakiri; Erwin F Wagner
Journal:  Mol Oncol       Date:  2013-02-05       Impact factor: 6.603

Review 8.  Functional and genetic deconstruction of the cellular origin in liver cancer.

Authors:  Jens U Marquardt; Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

9.  Loss of hepatocyte ERBB3 but not EGFR impairs hepatocarcinogenesis.

Authors:  Lawrence A Scheving; Xiuqi Zhang; Mary C Stevenson; Michael A Weintraub; Annam Abbasi; Andrea M Clarke; David W Threadgill; William E Russell
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-10-22       Impact factor: 4.052

10.  p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release.

Authors:  He-Xin Yan; Hong-Ping Wu; Hui-Lu Zhang; Charles Ashton; Chang Tong; Han Wu; Qi-Jun Qian; Hong-Yang Wang; Qi-Long Ying
Journal:  J Hepatol       Date:  2013-05-25       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.